HER-2 positive

We consider ET suitability to be the clinical assessment of whether a patient could benefit from ET, where benefit is defined not solely by tumor response but by a clinically relevant constellation of characteristics and markers possibly predicting the durability of disease response and symptom control. Several unresolved questions remain regarding issues such as disease heterogeneity, optimal treatment sequencing, and biomarker precision, but further work and ongoing studies will help to support the evolution of guidelines and provide clarity around the effective application of this quickly developing field to daily clinical practice.

Immunotherapy showed substantial benefits in improving pCR rates in both TNBC and HR+HER2- patients when combined with neoadjuvant chemotherapy, especially in lymph node-positive breast cancer patients.

Our findings revealed that statin use significantly enhanced the efficacy of T-DXd in both a preclinical HER2-negative rat model and patients with HER2-positive mBC. Prospective clinical trials are warranted to validate these observations.

P2, N=182, Recruiting, Hebei Medical University Fourth Hospital

Neoadjuvant chemotherapy with trastuzumab resulted in a clinical complete response, and total mastectomy yielded a pathological complete response...Furthermore, considering emerging evidence that some OBC may arise from axillary ectopic breast tissue, the present case - lacking any pathological features of ectopic tissue - is more consistent with a metastatic origin than with an ectopic primary, although a definitive distinction cannot be established. Lifelong surveillance is essential for patients with OBC, even after prolonged remission.

Most OOP expenditure was for trastuzumab. Current cancer support programs have potential to address the financial impact of their treatment.

Given the clinical severity, inpatient treatment was promptly initiated with trastuzumab and pertuzumab every three weeks, combined with weekly paclitaxel at a 50% dose reduction. In carefully selected patients, early and sustained HER2-directed therapy can lead to meaningful clinical recovery when options appear limited. Such cases help bridge the evidence gap for this high-risk group and may inform future therapeutic considerations.

We review the current epidemiologic, mechanistic, and clinical evidence on how the gut microbiome influences TNBC biology, with particular attention to the tumor immune microenvironment and response to therapy. We highlight protective and pro-tumorigenic microbial signatures, the impact of antibiotics and obesity, and emerging strategies, such as dietary modulation and microbiome-targeted interventions, that may ultimately be used to optimize TNBC management and improve patient outcomes.

She received six cycles of neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab. Persistent radiologic abnormalities may represent residual mucin rather than viable tumor cells, underscoring a potential limitation of imaging-based response evaluation. This report provides insight into response interpretation in this rare entity and supports the need for cautious clinical decision-making.

Furthermore, the DNA circuit-based signal generation module exhibits excellent universality and signal stability, allowing the method to be adapted for detecting other cancer cells, such as HER-2-positive BT-474 and MDA-MB-453 cells through simple aptamer replacement. Therefore, this work presents a reliable new tool for cancer cell detection, which holds great promise for playing an important role in future cancer diagnostic practices.

In patients aged ≥50 years, rim enhancement was associated with triple-negative subtype (P = 0.006).ConclusionBreast cancer in women aged ≤40 years exhibits distinct MRI features compared with older patients. Findings such as circumscribed margins, T2 iso/hyperintensity, and persistent enhancement may still reflect aggressive tumor biology in young women.

This study revealed the expression interplay and clinical significance of KIF2A and p53 in breast cancer. The identified association between KIF2A and p53 may provide insights for future research on their roles in breast cancer.